Patent intelligence · US
US 10183917
Tricyclic compounds and uses thereof in medicine
Tricyclic compounds and uses thereof in medicine
Patent details — US 10183917
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 22, 2019
- Expiration
- Jan 17, 2039
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Claims
- 12
- CPC classes
- A61K, A61K31/42, A61K31/4353, A61K31/4985
Quick answer
US 10183917 (Tricyclic compounds and uses thereof in medicine) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Jan 22, 2019. Expires Jan 17, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/42, A61K31/4353, A61K31/4985, A61K31/519, A61P
More from SUNSHINE LAKE PHARMA CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428432
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
granted -
US 12428389
Diarylamide compound and application thereof
granted -
US 12384853
Anti-HER2/PD1 bispecific antibody
granted -
US 12324812
Glucopyranosyl derivatives and their uses
granted -
US 12319748
Antibody binding to human HER2 and preparation method and use thereof
granted -
US 12312348
RET inhibitors, pharmaceutical compositions and uses thereof
granted -
US 12269886
Tetravalent bispecific antibody against PD-1 and PD-L1
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted
Frequently asked questions
What is US patent 10183917?
US 10183917 (Tricyclic compounds and uses thereof in medicine) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Jan 22, 2019. Expires Jan 17, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10183917?
SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.
When does US 10183917 expire?
Our index shows an expiration date of Jan 17, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.